A clinical trial of methylphenidate and lisdexamphetamine treatment in adults with attention-deficit hyperactivity disorder

Phase 1

• Conditions: Attention Deficit Hyperactivity Disorder; Therapeutic area: Psychiatry and Psychology [F] - Behaviours [F01]

• Registration Number: EUCTR2017-000368-14-SE
• Lead Sponsor: Sahlgrenska Univerisity Hospital Gothenburg

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2017-03-30
• Last Update Posted: 4 December 2018

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

Adults 18-45 years of age
Clinical diagnosis ADHD of any subtype and DSM 5 presentation
Intellectual ability in the normal range, according to clinical judgment
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 120
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Physical or mental limitations that make cognitive evaluations unsuitable.
Cardiovascular disease, seizures or other unstable medical conditions that might increase the risk for the subject.
Bipolar Disorder, Conduct Disorder, Psychosis, severe autism or other severe comorbid or medical conditions that in the investigator's opinion would make study participation unsuitable.
Substance abuse.
Subjects who has previously been treated with ADHD medication.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified